{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:16:38Z","timestamp":1792192598359,"version":"4.4.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The liver is the most common metastatic organ of neuroendocrine tumors (NETs). NET liver metastases (NETLMs) are categorized into simple liver metastasis (type I), complex liver metastasis (type II) and diffuse liver metastasis (type III), of which diffuse liver metastasis accounts for the highest percentage, up to 60-70%. Radical resection is recommended for all patients with type I and partial type II liver metastases without extrahepatic metastases in G1 and G2 grades, with a 5-year survival rate of 65%-70%. But for patients with G3 or type III liver metastases, treatment is controversial. Ablation and TAE\/TACE are commonly used localized treatments. Somatostatin analogue (octreotide and lanreotide) are efficacious in the treatment of better-differentiated NETs and can prolong the progression-free survival (PFS) of patients. Targeted drugs such as sunitinib, everolimus, sofantinib and cabozantinib are used to control tumor growth and improve symptoms. In addition, peptide receptor radionuclide therapy (PRRT), has been approved by the FDA for the treatment of progressive somatostatin receptor-positive gastroenteropancreatic NETs and has shown potential for prolonging PFS and improving survival. Multidisciplinary treatment is crucial for patients with NETLMs with high tumor load, and neoadjuvant therapy combined with surgery may lead to a better prognosis. However, the choice of treatment, indications for combination therapy, and disease prognosis still require further research and exploration. This review summarizes and evaluates the current treatment strategies and development trend of NETLM treatment through a literature review and provides new ideas as well as insights.<\/jats:p>","DOI":"10.3389\/fendo.2025.1601185","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:32Z","timestamp":1753330232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of liver metastases from non-functional gastroenteropancreatic neuroendocrine tumors: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Jun-shuai","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-qiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01217-z","article-title":"Neuroendocrine tumors: a relevant clinical update","volume":"24","author":"Rizen","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000225949","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors","volume":"90","author":"Akerstr\u00f6m","year":"2009","journal-title":"Neuroendocrinology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2020.04.02","article-title":"Neuroendocrine liver metastases: a contemporary review of treatment strategies","volume":"9","author":"Cloyd","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2023.08.011","article-title":"Management of neuroendocrine tumor liver metastases","volume":"226","author":"Harrelson","year":"2023","journal-title":"Am J Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.05.006","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review","volume":"162","author":"Moris","year":"2017","journal-title":"Surgery"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2015.08.010","article-title":"Treatment of neuroendocrine liver metastases","volume":"25","author":"Farley","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.v22.8","article-title":"Determinants of surgical resection for pancreatic neuroendocrine tumors","volume":"22","author":"Doi","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis","volume":"31","author":"Pavel","year":"2020","journal-title":"Treat follow-up Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The north american neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-5013-2","article-title":"Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: A nordic multicenter comparative study","volume":"23","author":"Haugvik","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"109678","DOI":"10.1016\/j.ejso.2025.109678","article-title":"Long-term outcome of cytoreductive hepatectomy in metastatic neuroendocrine neoplasia G3: A single center retrospective analysis","volume":"51","author":"Ammann","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12885-019-5457-z","article-title":"Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection","volume":"19","author":"Lv","year":"2019","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4654-5","article-title":"Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases","volume":"23","author":"Yuan","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12029-7","article-title":"Safety and outcomes of combined pancreatic and hepatic resections for metastatic pancreatic neuroendocrine tumors","volume":"29","author":"Gudmundsdottir","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.14701\/ahbps.21-101","article-title":"Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: A systematic review and meta-analysis","volume":"26","author":"Kulkarni","year":"2022","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i9.725","article-title":"Metastatic disease to the liver: Locoregional therapy strategies and outcomes","volume":"12","author":"Zane","year":"2021","journal-title":"World J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.20517\/2394-5079.2023.59","article-title":"The role of liver transplant for intrahepatic cholangiocarcinoma: the UK NHSBT liver advisory group pilot programme","volume":"9","author":"Hakeem","year":"2023","journal-title":"Hepatoma Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.024","article-title":"Functional imaging in liver tumours","volume":"65","author":"Ronot","year":"2016","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000805","article-title":"Complete remission of metastatic neuroendocrine paragastric carcinoma after \"Neoadjuvant\" Peptide receptor radionuclide therapy and surgery","volume":"40","author":"Schmidt","year":"2015","journal-title":"Clin Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2017.12.11","article-title":"Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology","volume":"7","author":"Shimata","year":"2018","journal-title":"Gland Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158899","article-title":"Neoadjuvant treatment of nonfunctioning pancreatic neuroendocrine tumors with [177Lu-DOTA0,Tyr3]Octreotate","volume":"56","author":"van Vliet","year":"2015","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000143301.56154.95","article-title":"Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study","volume":"240","author":"Mazzaferro","year":"2004","journal-title":"Ann Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","article-title":"Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up","volume":"148","author":"Akyildiz","year":"2010","journal-title":"Surgery"},{"key":"B33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jvir.2014.12.009","article-title":"Radiofrequency ablation for neuroendocrine liver metastases: a systematic review","volume":"26","author":"Mohan","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1148\/rg.25si055501","article-title":"Microwave ablation: principles and applications","author":"Simon","year":"2005","journal-title":"Radiographics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000580","article-title":"Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model","volume":"94","author":"Pillai","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/lap.2020.0558","article-title":"Operative microwave ablation for the multimodal treatment of neuroendocrine liver metastases","volume":"31","author":"Pickens","year":"2021","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000201208","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors","author":"Clouse","year":"1994","journal-title":"Digestion"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-018-02160-y","article-title":"Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes","volume":"42","author":"Zener","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-014-0914-1","article-title":"Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor","volume":"38","author":"Joskin","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00270-016-1535-7","article-title":"Chemoembolization of neuroendocrine liver metastases using streptozocin and tris-acryl microspheres: embozar (EMBOsphere + ZAnosaR) study","volume":"40","author":"Pelage","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm9072302","article-title":"The role of interventional radiology for the treatment of hepatic metastases from neuroendocrine tumor: an updated review","volume":"9","author":"Barat","year":"2020","journal-title":"J Clin Med"},{"key":"B44","article-title":"Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up","volume":"35","author":"Andrews","year":"1994","journal-title":"J Nucl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.23593","article-title":"Quantification of holmium-166 loaded microspheres: estimating high local concentrations using a conventional multiple gradient echo sequence with S0-fitting","volume":"35","author":"van de Maat","year":"2012","journal-title":"J Magn Reson Imaging"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2018.12.014","article-title":"Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis","volume":"21","author":"Frilling","year":"2019","journal-title":"HPB (Oxford)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2018.01.012","article-title":"Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review","volume":"100","author":"Jia","year":"2018","journal-title":"Eur J Radiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29207","article-title":"Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review","volume":"66","author":"Sangro","year":"2017","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-induced chronic hepatotoxicity: A single-center cohort analysis","volume":"30","author":"Currie","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/onco.13633","article-title":"Somatostatin analogs for pancreatic neuroendocrine tumors: any benefit when ki-67 is \u226510%","volume":"26","author":"Merola","year":"2021","journal-title":"Oncologist"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"R551","DOI":"10.1530\/ERC-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future","volume":"23","author":"\u00d6berg","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13063-023-07834-8","article-title":"Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET","volume":"25","author":"Singh","year":"2024","journal-title":"Trials"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01163-2","article-title":"Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results","volume":"24","author":"Labadzhyan","year":"2021","journal-title":"Pituitary"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1056","article-title":"A phase 3 large international noninferiority trial (MPOWERED): assessing maintenance of response to oral octreotide capsules in comparison to injectable somatostatin receptor ligands","volume":"5","author":"Fleseriu","year":"2021","journal-title":"J Endocrine Soc"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347512","article-title":"PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion","volume":"27","author":"Shimon","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0034","article-title":"Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors","volume":"28","author":"De Rycke","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"101667","DOI":"10.1016\/j.eclinm.2022.101667","article-title":"S-1\/temozolomide versus S-1\/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial","volume":"54","author":"Chi","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v109:8","article-title":"Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors","volume":"109","author":"Zhang","year":"2007","journal-title":"Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2024","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high\u2212dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2212dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003170","article-title":"Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable\/metastatic neuroendocrine tumors","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years' Assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001500","article-title":"Neoadjuvant capecitabine\/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors","volume":"49","author":"Squires","year":"2020","journal-title":"Pancreas"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v11.13","article-title":"Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02475-2","article-title":"Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study","volume":"71","author":"Caplin","year":"2021","journal-title":"Endocrine"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00980","article-title":"Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study","volume":"37","author":"Carmona-Bayonas","year":"2019","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001284","article-title":"Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not","volume":"41","author":"Yilmaz","year":"2020","journal-title":"Nucl Med Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e7131","DOI":"10.1002\/cam4.v13.8","article-title":"Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial","volume":"13","author":"Li","year":"2024","journal-title":"Cancer Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.672499","article-title":"Are markers of systemic inflammatory response useful in the management of patients with neuroendocrine neoplasms","volume":"12","author":"Giannetta","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2022.06.009","article-title":"Treatment strategies for neuroendocrine liver metastases: a systematic review","volume":"24","author":"Muttillo","year":"2022","journal-title":"HPB (Oxford)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1601185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:33Z","timestamp":1753330233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1601185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":84,"alternative-id":["10.3389\/fendo.2025.1601185"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1601185","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1601185"}}